Repeated measurements made under well-defined conditions allow estimation of long-term rate of bone loss and monitoring of treatment effect. This allows treatment decisions to be made. Bone mineral measurements can be used to assess the risk of fracture and, with it, the severity of bone loss. Osteoporosis and osteomalacia cannot be distinguished by bone mineral measurements because both more » are characterized by a decrease in content of bone mineral. This requires a different approach to data interpretation because decisions have to be made on the basis of a single measurement. Technical improvements have made these procedures available for the nontraumatic measurement of bone mineral in the management of the individual patient suspected of having osteoporosis or other bone loss. Single- and dual-photon absorptiometric methods have been used in the past to identify populations at risk for bone loss, to define the osteoporotic syndrome in terms of bone mass, and to evaluate treatment regimens to prevent bone loss. Because of the lack of demonstrated benefit and the associated complications of therapy, GH administration does not appear to be of value in the treatment of osteoporosis. Several side effects that are characteristic of acromegaly were observed, including hyperglycemia, hypertension, arthralgia, and the carpal tunnel syndrome. It may be concluded that under the conditions of this study, GH administration did not result in an increment in skeletal mass.
The bone biopsies displayed an increase in bone formation and resorption surfaces in response to treatment, but these changes were not statistically significant. Increases were noted in the urinary calcium excretion rate and in the urinary hydroxyproline excretion. Following the higher dose, no evidence of any anabolic effect was apparent in most patients (i.e., no increase in total more » body levels of Ca, Na, K, P, or Cl). The lower dosage (2 units) did not produce any appreciable change in the indices studied. Two dosage schedules were utilized for six months each: 2 units daily and 0.2 W/sup 3///sup 4/ units of GH daily (where W represents body weight expressed in kg). The effect of chronic administration of growth hormone (GH) to osteoporotic patients was studied using the techniques of total body neutron activation analysis, whole body counting, calcium tracer kinetics, photon absorptiometry, quantitative microradiography, and urinary hydroxyproline. BONE TISSUES MINERALS OSTEODENSITOMETRY PHOTON TRANSMISSION SCANNING CALCIUM ACTIVATION ANALYSIS MAN CHEMICAL COMPOSITION TISSUE DISTRIBUTION PATIENTS OSTEOPOROSIS BIOMEDICAL RADIOGRAPHY COMPARATIVE EVALUATIONS DIAGNOSTIC TECHNIQUES MEASURING METHODS QUANTITATIVE CHEMICAL ANALYSIS QUANTITY RATIO ALKALINE EARTH METALS ANIMALS BODY CHEMICAL ANALYSIS CONNECTIVE TISSUE DISEASES DISTRIBUTION ELEMENTS MAMMALS MEDICINE METALS NUCLEAR MEDICINE PRIMATES RADIOLOGY SKELETAL DISEASES TISSUES VERTEBRATES 550601* - Medicine- Unsealed Radionuclides in Diagnostics 560306 - Chemicals Metabolism & Toxicology- Man- = , Authors: Zanzi, I Colbert, C Bachtell, R Thompson, K Aloia, J Cohn, S Publication Date: Sun Jan 01 00:00: Research Org.: Brookhaven National Lab., Upton, NY (USA) Sponsoring Org.: USDOE OSTI Identifier: 6541207 Report Number(s): BNL-24459 CONF-780642-3 TRN: 79-002256 DOE Contract Number: EY-76-C-02-0016 Resource Type: Conference Resource Relation: Conference: Conference on bone mineral measurement, Toronto, Canada, Country of Publication: United States Language: English Subject: 62 RADIOLOGY AND NUCLEAR MEDICINE 63 RADIATION, THERMAL, AND OTHER ENVIRON.
0 kommentar(er)
